Table 1.

Characteristics of patients with SCD developing therapy-related myeloid malignancy after allogeneic hematopoietic cell transplantation at the National Institutes of Health Clinical Center

Patient ID	SCD complications	Age at AlloHCT, y	Donor type	Time from transplant to graft rejection	Time from transplant to myeloid malignancy, y	Cytogenetics at myeloid malignancy diagnosis	TP53 mutation and VAF at myeloid malignancy diagnosis
1	Stroke, CRI, recurrent VOC	37	Haplo	73 d	2	Complex	c.524G>A, 72.4% in bone marrow
2	Recurrent VOC, chronic pain	37	HLA-matched	6 mo	2.5	Complex*	c.658T>C, 4.5% in bone marrow
3	ESRD, pHTN, diastolic dysfunction	44	Haplo	7 mo	5	7q deletion	N/A

A total of 76 patients received AlloHCT for HbSS at this center; myeloid malignancy was only seen within those who did not engraft

CRI, chronic renal insufficiency; ESRD, end-stage renal disease; Haplo, haploidentical donor; N/A, not available; pHTN; pulmonary hypertension.

^*Patient 2 had complex cytogenetics at graft rejection 2 years before formal myeloid malignancy diagnosis (no aspirate collected at a later point).